WHO ICTRP trial
Neoadjuvant Zanidatamab + Tislelizumab + Gemcitabine/Cisplatin for Selective…
ChiCTR2500110562 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500110562 |
|---|---|
| Public title | Neoadjuvant Zanidatamab + Tislelizumab + Gemcitabine/Cisplatin for Selective Bladder Preservation in HER2-Positive MIBC |
| Scientific title | Selective Bladder Preservation After Neoadjuvant Zanidatamab Combined With Tislelizumab and Chemotherapy in Patients With HER2-Positive Muscle-Invasive Bladder Cancer: A Multicenter Study |
| Primary sponsor | Fujian Medical University Union Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Muscle invasive bladder cancer cancer |
| Interventions | Test Group:Zanidatamab + Tislelizumab + Cisplatin + Gemcitabine |
| Registration date | Oct 15, 2025 |
| Target size | Test Group:25 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: